[go: up one dir, main page]

PL2540843T3 - Polimorfizmy genetyczne w związanym z wiekiem zwyrodnieniu plamki żółtej - Google Patents

Polimorfizmy genetyczne w związanym z wiekiem zwyrodnieniu plamki żółtej

Info

Publication number
PL2540843T3
PL2540843T3 PL12185155T PL12185155T PL2540843T3 PL 2540843 T3 PL2540843 T3 PL 2540843T3 PL 12185155 T PL12185155 T PL 12185155T PL 12185155 T PL12185155 T PL 12185155T PL 2540843 T3 PL2540843 T3 PL 2540843T3
Authority
PL
Poland
Prior art keywords
age
macular degeneration
related macular
genetic polymorphisms
polymorphisms
Prior art date
Application number
PL12185155T
Other languages
English (en)
Inventor
Robert R Graham
Timothy W Behrens
Tsontcho Ianchulev
Howard Shapiro
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PL2540843T3 publication Critical patent/PL2540843T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6846Common amplification features
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00Reactions of nucleic acids characterised by
    • C12Q2531/10Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113PCR
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00Reactions of nucleic acids characterised by
    • C12Q2531/10Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/137Ligase Chain Reaction [LCR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL12185155T 2008-11-05 2009-11-05 Polimorfizmy genetyczne w związanym z wiekiem zwyrodnieniu plamki żółtej PL2540843T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11166708P 2008-11-05 2008-11-05
US17485609P 2009-05-01 2009-05-01
EP12185155.4A EP2540843B1 (en) 2008-11-05 2009-11-05 Genetic polymorphisms in age-related macular degeneration
EP09748682A EP2356250A2 (en) 2008-11-05 2009-11-05 Genetic polymorphisms in age-related macular degeneration

Publications (1)

Publication Number Publication Date
PL2540843T3 true PL2540843T3 (pl) 2014-12-31

Family

ID=41650496

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12185155T PL2540843T3 (pl) 2008-11-05 2009-11-05 Polimorfizmy genetyczne w związanym z wiekiem zwyrodnieniu plamki żółtej

Country Status (14)

Country Link
US (2) US20120003641A1 (pl)
EP (2) EP2540843B1 (pl)
JP (1) JP5701216B2 (pl)
KR (1) KR101719376B1 (pl)
CN (2) CN103333952B (pl)
AU (1) AU2009313475B2 (pl)
CA (1) CA2740242A1 (pl)
DK (1) DK2540843T3 (pl)
ES (1) ES2498274T3 (pl)
IL (1) IL211995A (pl)
MX (1) MX2011004763A (pl)
PL (1) PL2540843T3 (pl)
SI (1) SI2540843T1 (pl)
WO (1) WO2010054110A2 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
AU2009275110B2 (en) 2008-07-25 2012-08-16 Infocom Corporation Novel oncogene NRF2
EP2678441B1 (en) * 2011-02-23 2017-10-18 Sanofi Single nucleotide polymorphisms in the promoter of vegfa gene and their use as predictive markers for anti-vegf treatments
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN103717751A (zh) 2011-05-19 2014-04-09 塞昆纳姆股份有限公司 用于多重核酸鉴定的产品和方法
MX2014002144A (es) * 2011-08-26 2014-03-31 Hoffmann La Roche Metodo para predecir el beneficio clinico del tratamiento de los transtornos del desarrollo neurologico, neurologicos o neuropsiquiatricos.
PE20141562A1 (es) * 2011-10-14 2014-11-12 Genentech Inc Anticuerpos anti-htra1 y metodos de uso
US20140004105A1 (en) * 2012-06-29 2014-01-02 Sequenom, Inc. Age-related macular degeneration diagnostics
CR20160132A (es) * 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
SI3170005T1 (sl) 2014-07-18 2019-08-30 Sanofi Postopek napovedovanja izida zdravljenja z afliberceptom, pacienta, pri katerem obstaja sum, da je zbolel za rakom
WO2016100745A2 (en) * 2014-12-19 2016-06-23 Children's Hospital Medical Center Methods and compositions related to transplant-associated thrombotic microangiopathy
EP3286327B1 (en) 2015-04-24 2021-11-10 Agena Bioscience, Inc. Multiplexed method for the identification and quantitation of minor alleles and polymorphisms
CN104878105B (zh) * 2015-06-02 2017-10-31 北京医院 一种预测雷珠单抗治疗年龄相关性黄斑变性疗效的试剂
CN104894261B (zh) * 2015-06-02 2020-02-14 北京医院 一种预测雷珠单抗治疗年龄相关性黄斑变性疗效的试剂盒
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2017148904A1 (en) * 2016-02-29 2017-09-08 Franz Grus Predictive markers useful in the treatment of wet age-related macular degeneration
MX392422B (es) 2016-06-21 2025-03-24 Orion Ophthalmology LLC Derivados de prolinamida heterociclica
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113373236B (zh) * 2021-02-19 2021-12-31 中国科学院北京基因组研究所(国家生物信息中心) 一种获得中国人群个体年龄的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
CA2303206A1 (en) 1997-09-10 1999-03-18 University Of Maryland, Baltimore Method of amplifying dna and rna mismatch cleavage products
WO2006062716A2 (en) * 2004-11-18 2006-06-15 Yale University Methods and compositions for treating ocular disorders
WO2008103299A2 (en) * 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration

Also Published As

Publication number Publication date
IL211995A (en) 2014-04-30
ES2498274T3 (es) 2014-09-24
JP2012507988A (ja) 2012-04-05
AU2009313475B2 (en) 2016-06-02
AU2009313475A1 (en) 2010-05-14
WO2010054110A3 (en) 2010-08-19
CA2740242A1 (en) 2010-05-14
WO2010054110A2 (en) 2010-05-14
CN103333952B (zh) 2015-07-29
CN102203296B (zh) 2014-12-03
EP2540843A2 (en) 2013-01-02
IL211995A0 (en) 2011-06-30
CN102203296A (zh) 2011-09-28
JP5701216B2 (ja) 2015-04-15
EP2356250A2 (en) 2011-08-17
EP2540843A3 (en) 2013-05-29
MX2011004763A (es) 2011-06-01
HK1173751A1 (en) 2013-05-24
US20120003641A1 (en) 2012-01-05
BRPI0914368A2 (pt) 2015-10-20
EP2540843B1 (en) 2014-07-02
DK2540843T3 (da) 2014-09-01
KR101719376B1 (ko) 2017-03-23
CN103333952A (zh) 2013-10-02
KR20110081836A (ko) 2011-07-14
SI2540843T1 (sl) 2014-10-30
US20170159114A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
IL211995A0 (en) Genetic polymorphisms in age-related macular degeneration
IL247144A (en) Multiple genetic occurrences of age-dependent staining
PL2145914T3 (pl) Preparaty plastyfikatorów
PL2187880T3 (pl) Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej
EP2227780A4 (en) GENETIC ANALYSIS
IL193396A0 (en) Variants in complement regulatory genes predict age-related macular degeneration
EP2201087A4 (en) HYDROCRACK PROCEDURE
ZA200908481B (en) Compositions and methods for altering gene expression
ZA201100093B (en) Novel genes involved in biosynthesis
PL2252317T3 (pl) Leczenie zwyrodnienia plamki żółtej
GB0800702D0 (en) Genes
PL2100661T3 (pl) Kompleksowe kompozycje cyklopropenu
EP2292798A4 (en) HYBRIDIZATION IN SITU D ARN
GB2466379B (en) Protein stabilizer
IL190795A0 (en) Genes associated with macular degeneration
EP2249871A4 (en) OPHTHALMIC COMPOSITION
GB0816702D0 (en) Complement proteins
PL2127832T3 (pl) Materiał krawędziowy
HK1161310A (en) Genetic polymorphisms in age-related macular degeneration
TWI350891B (en) Omnibus quasi-hydrosystem
GB0704573D0 (en) Multi-use retaining means
HK1154406A (en) Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
GB0811149D0 (en) Gene
HU0800170V0 (en) Horizontal axle grinder
EP2280612A4 (en) METHOD FOR MAINTAINING INTESTINAL BACTERIA IN BALANCE